- Coordinator
- Deutsches Krebsforschungszentrum Heidelberg, Germany
- Runs
- 1 October 2024 to 30 September 2029
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €2.5m
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101141901
What the project is doing
In the project's own words, from its summary on CORDIS.
Personalized tumor immunotherapy - vaccines and T cell therapies - requires the selection of few immunogenic epitopes recognized by tumor-reactive T cell receptors (TCRs) from thousands of potential tumor antigens in each tumor. This selection is a huge challenge, particularly in brain tumors, where access to tumor tissue is limited and tumor-infiltrating T cells (TILs) are sparse. CENTRIC-BRAIN will reverse this epitope-centric approach by directly harnessing tumor-reactive orphan TCRs from TILs for personalized brain tumor immunotherapy.
Using human brain tumor tissue we have developed and experimentally validated predicTCR, a novel approach using machine learning and explainable AI to derive a classifier that predicts tumor-reactivity of such orphan TCRs based on the expression of signature genes with > 90% accuracy across multiple tumour entities. CENTRIC-BRAIN will employ predicTCR to develop a personalized adoptive cell therapy using transgenic T cells with tumor-specific TCRs and improved function.
CENTRIC-BRAIN hypothesizes that the signature genes underlying predicTCR determine the phenotypic and functional properties of tumor-reactive T cells and that predicted tumor-reactive orphan TCRs can be employed for adoptive therapy with personalized TCR-transgenic T cells. Aim 1 will refine predicTCR by characterizing the transcriptional programs and spatial distribution of tumor-reactive T cells in human brain tumor samples.
Aim 2 will define the functional relevance of transcriptional programs for tumor-reactive T cells in syngeneic humanized and patient-derived xenograft brain tumor models. Aim 3 will validate the predicted tumor-reactive orphan TCRs by adoptive transfer of T cells genetically engineered to express predicted tumor-reactive TCRs. CENTRIC-BRAIN will thus revolutionize precise and efficient implementation of personalized adoptive cell therapy for brain tumors using T cells expressing tumor-reactive patient-derived orphan TCRs.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Deutsches Krebsforschungszentrum Heidelberg | Heidelberg | Germany | Coordinator |
| Ruprecht-Karls-Universitaet Heidelberg | Heidelberg | Germany | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI